pharmaphorum January 3, 2025
Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.
News of the takeover came in the form of a LinkedIn post from the UK company’s former chief executive Mark Gaffney, now heading up Calluna Pharma, who wrote that the ophthalmology team at Regeneron is “uniquely positioned to maximise the use of Oxular’s proprietary technologies.” The terms of the acquisition have not been disclosed.
Oxular is working on the development of novel drug/device combinations for sight-threatening retinal disorders, which is a key area of focus for Regeneron. The US biopharma’s biggest product is Bayer-partnered Eylea/Eylea HD (aflibercept), which is used to treat diseases including age-related macular degeneration (AMD)...
Today's Sponsors
Today's Sponsor